Loading…
Bristol-Myers Squibb Company is projected to rise to $67.99 by 2027, a +18% move from its current price of $57.52. BMY is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $56.79 | $57.52 | $58.26 | 0.00% |
| May 30 | $56.50 | $57.53 | $58.57 | +0.01% |
| May 31 | $56.27 | $57.53 | $58.81 | +0.01% |
| Jun 1 | $56.08 | $57.53 | $59.02 | +0.02% |
| Jun 2 | $55.92 | $57.53 | $59.20 | +0.02% |
| Jun 3 | $55.77 | $57.54 | $59.36 | +0.03% |
| Jun 4 | $55.63 | $57.54 | $59.51 | +0.03% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $55.63 | $57.54 | $59.51 | +0.03% |
| Week 2 | $54.88 | $57.56 | $60.37 | +0.07% |
| Week 3 | $54.31 | $57.58 | $61.04 | +0.10% |
| Week 4 | $53.84 | $57.60 | $61.62 | +0.13% |
| Week 5 | $53.43 | $57.62 | $62.13 | +0.17% |
| Week 6 | $53.06 | $57.64 | $62.60 | +0.20% |
| Week 7 | $52.73 | $57.65 | $63.04 | +0.23% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Bristol-Myers Squibb Company is a biopharmaceutical company that discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. Its portfolio includes Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for relapsed or refractory large B-cell lymphoma; Opdualag for unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom.
It also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for relapsed or refractory multiple myeloma; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for a reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane for the treatment of breast cancer. Further, it provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; and NSCLC and pancreatic cancer.
It sells products to wholesalers, distributors, specialty pharmacies, and to lesser extent, retailers, hospitals, clinics, and government agencies. The company was founded in 1887 and is headquartered in Princeton, New Jersey; it was formerly known as Bristol-Myers Company.
BMY is a healthcare stock traded under the ticker BMY, with a current price of $59.46 and a market capitalization of $121.42B. It holds a market ranking of 128. The stock sits in the Healthcare sector, reflecting its biopharmaceutical focus.
The near-term outlook shows a flat to modestly higher path, with the 2026 average forecast equal to the current price, suggesting limited near-term upside. The longer-term view, however, points to substantial upside with multi-year forecasts indicating meaningful gains through 2030, 2040, and 2050. Overall, the stock is positioned for bullish momentum over the long horizon while presenting near-term stagnation in the forecast.
A major floor 7.8% below — a decisive break under it would weaken the trend.
The nearest floor, 3.2% below — buyers have tended to step in here.
The nearest ceiling, 5.3% above — a clean break opens room to run.
A major ceiling 9.3% above — clearing it would confirm fresh momentum.
Key BMY support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BMY market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $58.62 | Sell | $58.17 | Sell |
| MA 10 | $57.89 | Sell | $58.00 | Sell |
| MA 20 | $57.54 | Sell | $57.89 | Sell |
| MA 50 | $58.34 | Sell | $58.07 | Sell |
| MA 100 | $58.27 | Sell | $57.09 | Buy |
| MA 200 | $52.92 | Buy | $54.98 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 47.44 | Neutral |
| Stoch RSI (14) | 42.71 | Neutral |
| CCI (20) | -1.10 | Neutral |
| Williams %R (14) | -52.32 | Info |
| MACD (12,26,9) | 0.21 | Buy |
| ROC (12) | 2.42 | Buy |
| Bollinger %B (20,2) | 0.50 | Neutral |
| Stochastic %K (14) | 47.68 | Neutral |
| TRIX (15) | -0.07 | Sell |
| Awesome (5,34) | 0.59 | Buy |
| Ultimate (7,14,28) | 54.63 | Neutral |
| Momentum (10) | 1.07 | Buy |
| Aroon Osc (25) | -28.00 | Sell |
| Hull MA (9) | 58.86 | Sell |
| ADX (14) | 10.82 | Neutral |
| ATR (14) | 0.66 | Info |
The 30-day technical picture is bullish, with RSI14 at 60 and the stock trading above near-term moving averages. The 50-day simple moving average is $58.40, while the 200-day simple moving average is $52.79, signaling a constructive trend. Immediate support is seen at $55.67 and resistance at $60.59, framing a measured path higher.
The 30-day trading range spans from $54.81 to $64.51, indicating price momentum within a defined window.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $53.06 | $57.52 | $74.91 | 0% | Neutral | |
| $55.54 | $67.99 | $87.12 | +18% | Neutral | |
| $59.47 | $74.13 | $97.46 | +29% | Bullish | |
| $62.25 | $78.76 | $105.71 | +37% | Bullish | |
| $69.97 | $89.71 | $122.53 | +56% | Bullish | |
| $81.69 | $106.01 | $147.05 | +84% | Bullish | |
| $93.00 | $122.04 | $171.67 | +112% | Bullish | |
| $98.03 | $129.97 | $185.17 | +126% | Bullish | |
| $96.40 | $129.09 | $186.09 | +124% | Bullish | |
| $106.13 | $143.45 | $209.07 | +149% | Bullish | |
| $151.80 | $213.95 | $326.69 | +272% | Bullish | |
| $294.67 | $445.37 | $728.75 | +674% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $53.06 | $57.52 | $67.47 | +0.00% |
| June 2026 | $49.61 | $57.87 | $68.82 | +0.61% |
| July 2026 | $49.24 | $57.77 | $69.35 | -0.18% |
| August 2026 | $50.17 | $59.13 | $71.50 | +2.35% |
| September 2026 | $50.49 | $59.72 | $72.65 | +1.01% |
| October 2026 | $49.49 | $58.74 | $71.83 | -1.65% |
| November 2026 | $49.54 | $58.98 | $72.47 | +0.41% |
| December 2026 | $50.84 | $60.70 | $74.91 | +2.92% |
Click any year to see its month-by-month BMY forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, BMY is projected to trade between $53.06 and $74.91, averaging $57.52 — a potential gain of 0% from today's $57.52. A consolidation phase looks the most probable path here.
Bristol-Myers Squibb Company's 2027 outlook centres on $67.99, within a $55.54 to $87.12 range. That is up +18% on the projected 2026 average. That marks a +18% change versus current levels. Price action looks broadly range-bound.
By 2028, BMY could reach as high as $97.46, with a base case around $74.13 and support toward $59.47 — roughly +29% from $57.52. Buyers look set to stay in control over this stretch.
Expect BMY to range from $62.25 to $105.71 through 2029. The $78.76 average target implies a +37% move from current prices. That is up +6% on the projected 2028 average. Momentum favours further upside here.
The BMY price prediction for 2030 points to an average of $89.71 (low $69.97, high $122.53) — a potential gain of +56% on today's $57.52. Buyers look set to stay in control over this stretch.
In 2031, BMY is projected to trade between $81.69 and $147.05, averaging $106.01 — a potential gain of +84% from today's $57.52. That is up +18% on the projected 2030 average. Momentum favours further upside here.
Bristol-Myers Squibb Company's 2032 outlook centres on $122.04, within a $93.00 to $171.67 range. That is up +15% on the projected 2031 average. That marks a +112% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, BMY could reach as high as $185.17, with a base case around $129.97 and support toward $98.03 — roughly +126% from $57.52. Momentum favours further upside here.
Expect BMY to range from $96.40 to $186.09 through 2034. The $129.09 average target implies a +124% move from current prices. That is -1% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
The BMY price prediction for 2035 points to an average of $143.45 (low $106.13, high $209.07) — a potential gain of +149% on today's $57.52. Momentum favours further upside here.
In 2040, BMY is projected to trade between $151.80 and $326.69, averaging $213.95 — a potential gain of +272% from today's $57.52. That is up +49% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Bristol-Myers Squibb Company's 2050 outlook centres on $445.37, within a $294.67 to $728.75 range. That is up +108% on the projected 2040 average. That marks a +674% change versus current levels. Momentum favours further upside here.
Investing $1,000 in BMY today (≈ 17.385257 BMY) could be worth
$7,742.9
+$6,742.9 (+674%) by 2050 · US Dollar
Based on the average projected BMY price of $445.37 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BMYwould be worth at today's price.
$1,000 invested in BMY on May 27, 2025 (≈ 21.326509 BMY) would be worth
$1,226.7
+$226.7 (+22.7%) today · 1.23× · US Dollar
Based on a BMY entry price of $46.89 vs. today's $57.52.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $58.54 | $982.58 | -1.7% |
| 1 month ago | $57.78 | $995.5 | -0.4% |
| 3 months ago | $61.1 | $941.41 | -5.9% |
| 6 months ago | $49.2 | $1,169.11 | +16.9% |
| 1 year ago | $46.89 | $1,226.7 | +22.7% |
| All time (5.0y) ago | $65.1 | $883.56 | -11.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BMY forecast.
Our base-case forecast reaches $120.00 around 2032.
Implied market cap at $120.00: $245.05B
Multi-year forecasts show a steady uplift from the 2026 baseline. The 2026 average is $59.46 with an ROI of 0% (neutral sentiment). By 2027 the average rises to $70.86 (ROI 19.2%), and by 2028 to $78.27 (ROI 31.6%).
The 2029 forecast is $83.44 (ROI 40.3%), and 2030 is $95.53 (ROI 60.7%), with a bullish outlook. Beyond 2030, the path continues higher: 2031 average $114.40 (ROI 92.4%), 2032 $131.23 (ROI 120.7%), 2033 $139.54 (ROI 134.7%), 2034 $140.17 (ROI 135.7%), and 2035 $156.10 (ROI 162.5%). The long-term view extends further to 2040 with an average of $235.47 (ROI 296%) and to 2050 with an average of $494.97 (ROI 732.4%).
These figures depict substantial upside potential but come with inherent uncertainty and are not guarantees.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $95.53 with a max of $130.51 and a min of $74.50, with an ROI of 60.7% and a bullish sentiment.
Near term (2026) shows an average price of $59.46 with ROI of 0% and a neutral sentiment, while the long-term outlook is bullish, with substantial upside including $95.53 average by 2030 and $494.97 average by 2050.
Yes, the forecast indicates potential to reach near or above $200 by the mid-2030s, with a max forecast of $202.09 in 2034 and $227.55 max in 2035.
Momentum is bullish with RSI14 at 60. The 50-day SMA is $58.40, the 200-day SMA is $52.79, support is at $55.67, resistance at $60.59, and the 30-day range is $54.81 to $64.51.
The current price is $59.46 and the market capitalization is $121.42B; the stock is ranked 128 by market cap.
Bristol-Myers Squibb Company Community Discussion
0Share your Bristol-Myers Squibb Company price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.